Skip to content
OpenCapital
Get started

Lexicon Pharmaceuticals LXRX Accrued research and development services current

Other financials

Income statement

See full
Revenue$21.1M+1,572%
Gross profit$21.0M+1,604%
Operating income-$996.0K+96.1%
Net income-$1.0M+95.9%
EPS (diluted)$0.00+100%

Balance sheet

See full
Cash & equivalents$67.1M+6.7%
Total debt$57.7M-45.7%
Total equity$202.9M+64.9%
Total assets$268.8M-9.7%

Cash flow

See full
Operating cash flow-$14.7M+66.4%
CapEx--100%
Free cash flow-$17.2M+21.5%

Valuation

See full
Market cap$1.02B+273%
Enterprise value$1.01B+219%
P/S14.6×+5.9×

Profitability

See full
Gross margin99.5%+1.5pp
Operating margin-34.8%-16.8pp
Net margin-37.5%-18.1pp
FCF margin-578.5%-283pp

Returns & leverage

See full
Return on equity-16%-7.2pp
Debt / equity0.3×-0.6×
Current ratio18.8×+16.6×

Where this comes from

Reported directly by Lexicon Pharmaceuticals in its filing.

Tagged under the XBRL concept lxrx:AccruedResearchAndDevelopmentServicesCurrent.

The official record: Lexicon Pharmaceuticals’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →

Ask your AI about Lexicon Pharmaceuticals's accrued research and development services current.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Lexicon Pharmaceuticals's accrued research and development services current?
Lexicon Pharmaceuticals (LXRX) reported accrued research and development services current of $618K in Q1 2026.
How has Lexicon Pharmaceuticals's accrued research and development services current changed year-over-year?
Lexicon Pharmaceuticals's accrued research and development services current decreased by 90.1% year-over-year, from $6.23M to $618K.
What is the long-term trend for Lexicon Pharmaceuticals's accrued research and development services current?
Over 5 years (2020 to 2025), Lexicon Pharmaceuticals's accrued research and development services current has grown at a -33.2% compound annual growth rate (CAGR), from $21.96M to $2.93M.